It remains uncertain whether lower CD19 expression is clinically relevant for outcomes of CD19 CAR-T therapy of large B-cell lymphoma (LBCL). We conducted an integrative analysis of tumor CD19 levels with centralized quantitative assessment by flow cytometry (FC), immunohistochemistry and RNA-sequencing in a LBCL cohor...
M. Corona, Aaron Gillmor, K. Argyropoulos et al.· Blood Cancer Discovery· 0 citations
BACKGROUND
Relapse remains the leading cause of treatment failure following allogeneic hematopoietic stem cell transplantation (alloHCT) for high-risk myeloid malignancies. Epigenetic dysregulation contributes to leukemogenesis and therapeutic resistance.
OBJECTIVE
OBJECTIVE: : To investigate whether pre-transplant e...
Mohammad Alhomoud, Franco Castillo Tokumori, N. Chokr et al.· Transplantation and Cellular...· 0 citations
This review summarizes the current landscape of POC CAR T-cell manufacturing, emphasizing clinical outcomes, economic sustainability, and regulatory considerations, and discusses emerging technologies, including allogeneic CAR T-cell platforms, artificial intelligence-driven manufacturing, and in vivo gene editing, tha...
Abdulrahman Nasiri, R. El Fakih, C. Chabannon et al.· Bone Marrow Transplantation· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.